Navigation Links
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
Date:5/20/2008

Data on Newly-Approved Cimzia(R) Presented at Digestive Disease Week (DDW)

SAN DIEGO, May 20 /PRNewswire/ -- UCB announced today that data presented at Digestive Disease Week reaffirm the long-term, sustainable efficacy and safety of Cimzia(R) (certolizumab pegol) at stable doses in treating patients with moderate to severe Crohn's disease. Data also showed continued remission amongst the majority of responders and the remission rate remained stable in many of the patients who were re-induced with Cimzia(R). These results represent data from the PRECiSE trial program, which evaluated more than 1,300 patients receiving continuous treatment with Cimzia(R) (400 mg) for up to 18 months.

"The long-term Cimzia(R) data provide very important information for clinical practitioners treating people with Crohn's disease," said study investigator Gary R. Lichtenstein, M.D., professor of medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa. "In clinical trials, Cimzia(R) showed remarkable and sustainable long-term results without the need for dose escalation. Further, patients can achieve long-term symptom relief and remission regardless of the magnitude and rapidity of onset of the initial response."

Cimzia(R) is the first and only PEGylated anti-TNF (Tumor Necrosis Factor alpha) antibody approved for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) was approved by the U.S. Food and Drug Administration (FDA) on April 22, 2008.

UCB, the manufacturer of Cimzia(R), presented analyses of the PRECiSE 3 and 4 open-label extension studies, which demonstrated the long-term efficacy of Cimzia(R) in treating Crohn's disease. PRECiSE 3 data showed that eight out of ten patients who were in remission at six months stayed in remission for up to 18 months. Furthermore, 35 percent of pat
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
3. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
4. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
7. Gene Therapy Provides Vision to People who Were Nearly Blind
8. Arpida Provides Further Comments on the Pivotal Phase III Trials
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/18/2013)... MILAN , June 19, 2013 ... in fluctuating Parkinson,s disease (PD) patients as add-on ... clinically important improvement in motor symptoms in fluctuating ...   Newron Pharmaceuticals S.p.A. ("Newron"), a ... and pain therapies, and its partner Zambon S.p.A., ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6
... 2011 Asante Solutions, Inc. (Asante), a medical device ... the CE mark for its Pearl Insulin Pump, the ... The CE mark is a European proof of conformity ... environmental requirements. Asante has begun discussions with potential distribution ...
... 12, 2011 PRA International, a leading Clinical Research Organization, ... (SRM) group will speak at the World Drug Safety Congress ... will also host an exhibit at booth #2. ... chair the first breakout stream, "Operational Safety," on 13 April ...
Cached Medicine Technology:Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2PRA International Experts to Speak at Drug Safety Conference 2
(Date:6/19/2013)... years, Alzheimer,s researchers have focused on two proteins that ... may contribute to the disease: plaques made up of ... tau. , But for the first time, an Alzheimer,s ... independently, but at the interaction of the two proteins ... post-mortem Alzheimer,s patients and in mouse brains with Alzheimer,s ...
(Date:6/19/2013)... that the incidence of cancer is many fold higher ... have an inadequate understanding on how best to treat ... are occasionally included in clinical trials, those elderly patients ... patients. Thus, the broader elderly patient population is not ... the Elderly Task Force is now starting a new ...
(Date:6/19/2013)... IL (PRWEB) June 19, 2013 Chicago is ... the 31st, 48th and 50th Chicago Wards will require landlords ... – or face fines. The ordinance also makes ... complying with all treatment requests – which often include disposing ... pest control company Orkin reported that it did more bed ...
(Date:6/19/2013)... The Cancer Support Community (CSC), an international nonprofit organization, ... whole patient with the launch today of the Cancer ... event, held at the Newseum, will feature a keynote ... members who have made a significant impact on cancer ... engaged in the cancer journey. , ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 A brain ... for those closest to them. The sudden onset of ... brain tumor has on a patient’s behavioral and cognitive ... both the patient and family. The American Brain ... July 26 and Saturday, July 27 in Chicago, focuses ...
Breaking Medicine News(10 mins):Health News:New Alzheimer's research suggests possible cause: The interaction of proteins in the brain 2Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Chicago Ordinance Requires Landlords and Tenants to Take Responsibility for Bed Bugs 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 2Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 3
... 2, 2010 As part of a national clinical ... in effectiveness between two popular treatments for one of ... incontinence. Stress incontinence affects up to 50 percent ... their lives. Women with stress incontinence experience leakage during ...
... PeriGen, ... clinical and financial value, today announced that Donald A. Deieso, Ph.D., the Company’s Chairman ... 2010 Award in New Jersey. , ... Princeton, NJ -- PeriGen, Inc. , the only OB-specific risk ...
... has received the human papillomavirus (HPV) vaccine to help prevent ... Washington University School of Medicine in St. Louis. The ... American Journal of Preventive Medicine . The HPV vaccine ... of which are found in about 70 percent of all ...
... Healthcare reform -- and the many options for fixing a broken ... According to an article in the June issue of the ... many who suffer from disabling arthritis of the hip and knee, ... crisis to medical care. "This is not a just a ...
... if young adults were more fit, 34% of high blood ... News) -- Low levels of physical activity and fitness significantly ... study of young adults shows. , The study, released online ... issue of the journal Hypertension , found that about ...
... have paired up to create technology that has ... the first procedure-based, hands-on surgical training software. Their ... surgeons through real-time operative procedures using the Robotic ... MD, a staff physician in Urology at Roswell ...
Cached Medicine News:Health News:UT Southwestern investigators perform head-to-head comparison of incontinence treatments 2Health News:Donald A. Deieso, Ph.D., Chairman & CEO, PeriGen, Inc. Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist 2Health News:Donald A. Deieso, Ph.D., Chairman & CEO, PeriGen, Inc. Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist 3Health News:One-third of young girls get HPV vaccine to prevent cervical cancer 2Health News:One-third of young girls get HPV vaccine to prevent cervical cancer 3Health News:Health-care economics and policy: It's a perfect storm 2Health News:Health-care economics and policy: It's a perfect storm 3Health News:Being Young and Sedentary Raises Hypertension Risk Later 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 3Health News:Surgeon-engineer team produce training software for robot-assisted surgery 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: